Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1715 • ACR Convergence 2022
Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice
Xiaoqing Zheng¹, Mikhail Dozmorov², Colleen Strohlein¹, Sheldon Bastacky¹ and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Virginia Commonwealth University, Richmond, VA
Background/Purpose: Enhancer of zeste homolog 2 (EZH2) has been shown to regulate early B cell development and the differentiation of antibody secreting cells (ASCs). We…
Abstract Number: 2019 • ACR Convergence 2022
Fine Mapping of the Sjögren’s Disease and Systemic Lupus Erythematosus DDX6-CXCR5 Risk Interval Reveals Common SNPs with Functional Significance in Immune and Salivary Gland Cells
Mandi Wiley¹, Bhuwan Khatri¹, Kandice Tessneer¹, Michelle Joachims¹, Anna Stolarczyk¹, Anna Nagel¹, Astrid Rasmussen¹, Professor Simon Bowman², Lida Radfar³, Roald Omdal⁴, Marie Wahren-Herlenius⁵, Blake Warner⁶, Torsten Witte⁷, Roland Jonsson⁸, Maureen Rischmueller⁹, Patrick Gaffney¹, Judith James¹, Lars Ronnblom¹⁰, Hal Scofield¹, Xavier Mariette¹¹, Fai Ng¹², Gunnel Nordmark¹⁰, Betty Tsao¹³ and Christopher Lessard¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University Hospitals Birmingham, Birmingham, United Kingdom, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Stavanger University, Stavanger, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Institutes of Health, Bethesda, MD, ⁷MH-Hannover, Hannover, Germany, ⁸University of Bergen, Bergen, Norway, ⁹RheumatologySA, Adelaide, Australia, ¹⁰Uppsala University, Uppsala, Sweden, ¹¹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹²Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹³Medical University of South Carolina, Charleston, SC
Background/Purpose: Sjögren's Disease (SjD) and Systemic Lupus Erythematosus (SLE) share several characteristics and have similar genome-wide significant associations in the DDX6-CXCR5 locus. Fine mapping of…
Abstract Number: 2066 • ACR Convergence 2022
Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population
Daniela Marengo-Rodriguez¹, Astrid Hernandez-De La Torre¹, Maria Jose Chavez-Barajas¹, André Fortanell-Meza², Ana Barrera-Vargas², Diego San Agustin-Morales² and Javier Merayo-Chalico³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Patients with SLE present with greater sexual dysfunction (SxD) than patients with other chronic diseases [1]. These patients tend to be younger compared to…
Abstract Number: 2084 • ACR Convergence 2022
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus
Naveen R¹, Elena Nikiphorou², Mrudula Joshi³, Parikshit Sen⁴, Vishwesh Agarwal⁵, Sinan Kardes⁶, James B. Lilleker⁷, Hector Chinoy⁸, Oliver Distler⁹, Minchul Kim¹⁰, Ai Lyn Tan¹¹, Samuel Shinjo¹², Babur Salim¹³, Tamer A Gheita¹⁴, Nelly Ziade¹⁵, Tsvetelina Velikova¹⁶, Tulika Chatterjee¹⁰, Arvind Nune¹⁷, Marcin Milchert¹⁸, Abraham Edgar Gracia-Ramos¹⁹, Albert Selva O’Callaghan²⁰, Miguel Angel Saavedra Salinas²¹, Lorenzo Cavagna²², Masataka Kuwana²³, Johannes Knitza²⁴, Jessica Day²⁵, Ashima Makol²⁶, Rohit Aggarwal²⁷, Vikas Agarwal¹, Latika Gupta²⁸, Lisa S Traboco²⁹, CoVAD Study Group³⁰ and Ioannis Parodis³¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Leiden University Medical Center & King's College London, London, United Kingdom, ³Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁴Maulana Azad Medical College, New Delhi, India, ⁵Mahatma Gandhi Missions Medical College, Lucknow, India, ⁶Istanbul University, Istanbul, Turkey, ⁷The University of Manchester, Manchester, United Kingdom, ⁸The University of Manchester, Sale, United Kingdom, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ¹⁰University of Illinois College of Medicine Peoria, Peoria, IL, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ¹³Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹⁴Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁵Saint-Joseph University, Beirut, Lebanon, ¹⁶Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁷Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ¹⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁹Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²⁰Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²¹IMSS, Ciudad de México, Mexico, ²²Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁵Walter and Eliza Hall Institute, Melbourne, Australia, ²⁶Mayo Clinic, Rochester, MN, Rochester, MN, ²⁷Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²⁹St Luke's Medical Center - BGC, Manila, Philippines, ³⁰CoVAD study group, Wolwehampton, United Kingdom, ³¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The COVID-19 vaccination in autoimmune diseases (COVAD) study is a large-scale real-world survey on COVID-19 vaccine safety in autoimmune rheumatic diseases (AIRDs), including systemic…
Abstract Number: 2104 • ACR Convergence 2022
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Jennifer Rogers¹, Amanda Eudy², Roberta Alexander³, David Pisetsky⁴, John Conklin³, Kai Sun⁵, Lisa Criscione-Schreiber⁶, Jayanth Doss⁵, Rebecca Sadun⁵, Mithu Maheswaranathan¹ and Megan Clowse⁵, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Exagen, Inc., Vista, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Manifestations of SLE can be divided into two subtypes. Type 1 SLE includes classic SLE manifestations that are driven by autoimmune inflammatory mechanisms. Type…
Abstract Number: 2265 • ACR Convergence 2022
Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Henri Tiedge¹, ILHAM MUSLIMOV², Valerio Berardi², Stacy Stephenson³, Ellen M. Ginzler⁴, Anca Askanase⁵ and John Hanly⁶, ¹SUNY, Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, NY, ³SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, ⁴SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
Abstract Number: 0066 • ACR Convergence 2022
Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database
Emily Smitherman¹, Rouba Chahine¹, Aimee Hersh² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Data is lacking regarding modern real-world practices and disease outcomes of individuals with childhood-onset systemic lupus erythematosus (cSLE) and lupus nephritis, especially across multiple…
Abstract Number: 0186 • ACR Convergence 2022
Evaluating the Effectiveness & Impact of an In-Person Peer Support Group That Transitioned to a Virtual Platform During the COVID-19 Pandemic
Giselle Rodriguez¹, Priscilla Calvache¹, Lillian Mendez¹, Kimberly Cabrera¹, Roberta Horton¹, Lisa Imundo² and Jillian Rose-Smith¹, ¹Hospital for Special Surgery, New York, NY, ²New York Presbyterian Hospital - Columbia Campus, New York, NY
Background/Purpose: Studies have demonstrated the benefits of online peer support forums in meeting the mental health, disease self-management & coping needs of people living with…
Abstract Number: 0332 • ACR Convergence 2022
Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE)
Yoshiyuki Arinuma¹, Yasuhiro Hasegawa², Yu Matsueda², Kenji Oku³ and Kunihiro Yamaoka⁴, ¹Kitasato University, Kanagawa, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Kitasato University, Chigasaki, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Microglial activation is critical for behavioral abnormalities in a mouse model of diffuse NPSLE following anti-glutamate receptor subunit GluN2 antibody (anti-GluN2) exposure to neurons.…
Abstract Number: 0349 • ACR Convergence 2022
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
Emma Materne¹, Hyon Choi², Baijun Zhou¹, Karen Costenbader³, Yuqing Zhang⁴ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA
Background/Purpose: Belimumab, a biologic B-Lymphocyte stimulator (BLyS) inhibitor, was FDA-approved in 2011 for the treatment of active SLE. Initial phase 3 placebo-controlled trials found no…
Abstract Number: 0371 • ACR Convergence 2022
A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)
Meggan Mackay¹, Robert Zurier², Diane Kamen³, Fotios Koumpouras⁴, Anca Askanase⁵, Kenneth Kalunian⁶, Steffan Schulz⁷, Giovanni Franchin⁸, Nancy Olsen⁹, Andreea Coca¹⁰, Roberto Caricchio¹¹, Maureen McMahon¹², Maria Dall'Era¹³, Amit Saxena¹⁴, Megan Clowse¹⁵, Stanley Ballou¹⁶, Linna Ding¹⁷, Beverly Welch¹⁸, Jessica Springer¹⁹, Andrew Shaw¹, Lynette Keyes-Elstein²⁰, Kaitlyn Steinmiller²¹, Amanda Mickey²¹, Cynthia Aranow¹ and Betty Diamond¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Feinstein Institutes, Wyckoff, NJ, ³Medical University of South Carolina, Charleston, SC, ⁴Yale School of Medicine, New Haven, CT, ⁵Columbia University Medical Center, New York, NY, ⁶University of California San Diego, La Jolla, CA, ⁷Univ Pennsylvania, Philadelphia, PA, ⁸BronxCare, Feinstein Institutes, Manhasset, NY, ⁹Penn State University/Milton S Hershey, Hershey, PA, ¹⁰UPMC, Pittsburgh, PA, ¹¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ¹²University of California Los Angeles, Los Angeles, CA, ¹³University of California, Division of Rheumatology, San Francisco, CA, ¹⁴NYU School of Medicine, New York, NY, ¹⁵Duke University, Durham, NC, ¹⁶Case Western Reserve University - Metro Health, Cleveland, OH, ¹⁷NIH NIAID, Rhockvile, MD, ¹⁸NIAID/NIH, Bethesda, MD, ¹⁹NIH/NIAID, Rockville, MD, ²⁰Rho, Chapel Hill, NC, ²¹Rho Inc, Durham, NC
Background/Purpose: Musculoskeletal (MSK) symptoms are common in SLE, often associate with debilitating pain requiring immunosuppressive treatment. JBT-101 is a non-psychotropic, non-immunosuppressive, cannabinoid receptor 2 agonist…
Abstract Number: 0636 • ACR Convergence 2022
Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
Andrea Fava¹, Carla J. Guthridge², Joseph Kheir², Catriona Wagner³, Michelle Petri⁴, Jill Buyon⁵, Betty Diamond⁶, the Accelerating Medicines Partnership (AMP) RA/SLE⁷, Joel Guthridge² and Judith James², ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Multiple Insitutions
Background/Purpose: There is a pressing need to identify novel therapeutic approaches and noninvasive biomarkers in lupus nephritis (LN). In this study, we quantified serum soluble…
Abstract Number: 0656 • ACR Convergence 2022
Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Ying Chen², Xinzhuang Yang³, Qian Wang⁴, JIULIANG ZHAO⁵, Xiaoyue Deng¹, Shengjie Li³, Yongtai Liu⁶, Zhuang Tian⁶, Juan Shen², Qijun Liao², Yanhong Wang⁷, Xianbo Zuo⁸, Xuejun Zhang⁹, MENGTAO LI¹, Yong Cui⁸, Xueqing Yu¹⁰ and Xiaofeng Zeng¹¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ²BGI-Shenzhen, Shenzhen, China, ³Medical Research Center, State Key laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Peking Union Medical College Hospital, Beijing, China, ⁵Beijing Union Medical College Hospital, Beijing, China, ⁶Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁷Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁸Department of Dermatology, China-Japan Friendship Hospital, Beijing, China, ⁹Institute of Dermatology, Anhui Medical University, Hefei, China, ¹⁰Division of Nephrology, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, ¹¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare and severe complication of systemic lupus erythematosus (SLE). Human leucocyte antigen (HLA) gene variants in the major…
Abstract Number: 0730 • ACR Convergence 2022
Improving Mental Health Services in Children and Adolescents with Systemic Lupus Erythematosus by Establishing a Mental Health Care Navigator
Colleen Correll, Erika Vaughn, Amanda Schlesinger and Danielle Bullock, University of Minnesota, Minneapolis, MN
Background/Purpose: Anxiety and depression are three times more common in children with childhood onset-systemic lupus erythematosus (cSLE) compared to their peers, and both are associated…
Abstract Number: 0961 • ACR Convergence 2022
The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series
Francesca Crisafulli¹, MARIA CHIARA GERARDI², Maria Letizia Urban³, Margherita Zen⁴, Melissa Padovan⁵, Valentina Canti⁶, Emanuela Praino⁷, Cecilia Nalli¹, Francesca Ruffilli⁵, Francesca Saccon⁸, Micaela Fredi⁹, Liala Moschetti¹, Giacomo Emmi³, Luca Iaccarino⁴, Andrea Doria¹⁰, Leonardo Santo⁷, Franco Franceschini¹, Laura Andreoli¹ and Angela Tincani¹¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia and Rheumatology Unit, ASST G.O.M. Niguarda, Milan, Milano, Italy, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy, ⁵Rheumatology Unit, Azienda Ospedaliero-Universitaria of Ferrara, Ferrara, Italy, ⁶Division of Immunology, IRCCS San Raffaele Institute, Milano, Italy, ⁷Rheumatology Unit, Presidio Ospedaliero ‘Mons. Dimiccoli’, Barletta, Italy, ⁸Unit of Rheumatology, Department of Medicine, University of Padova and Fondazione Villa Salus, Mestra, Venezia, Italy, ⁹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Manerbio, Italy, ¹⁰Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Via Giustiniani, 2, 35128 Padova, Italy., Padova, Italy, ¹¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy
Background/Purpose: Belimumab (BEL) is an anti-BLyS monoclonal antibody approved for SLE treatment. As few data about BEL use with regard to pregnancy are available, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].